A
1.69
-0.06 (-3.43%)
| Previous Close | 1.75 |
| Open | 1.85 |
| Volume | 6 |
| Avg. Volume (3M) | 9,369 |
| Market Cap | 62,361,508 |
| Price / Sales | 15.50 |
| Price / Book | 2.45 |
| 52 Weeks Range | |
| Earnings Date | 8 Aug 2025 - 22 Aug 2025 |
| Operating Margin (TTM) | -1,220.88% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 118.00% |
| Total Debt/Equity (MRQ) | 106.83% |
| Current Ratio (MRQ) | 1.41 |
| Operating Cash Flow (TTM) | -51.82 M |
| Levered Free Cash Flow (TTM) | -30.61 M |
| Return on Assets (TTM) | -32.84% |
| Return on Equity (TTM) | -103.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Adlai Nortye Ltd. | Mixed | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.25% |
| % Held by Institutions | 0.18% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |